Bojangles’ trades as part of the restaurants industry and is in the consumer cyclical sector. The company CEO is James R. Kibler. Bojangles Inc is a restaurant operator and franchisor. It has company restaurants, party franchised restaurants, and independent franchised restaurants operating under the Bojangles’ name.

Previous Intraday Performance:

The BOJA shares had a previous change of -0.06% which opened at 16.09 and closed at 16.09. It moved to an intraday high of 16.10 and a low of 16.08.

SeekingAlpha:  Buyout of Bojangles’ closes

Historical Performance:

Over the last five trading days, BOJA shares returned 0.31% and in the past 30 trading days it returned 0.44%. Over three months, it changed 5.37%. In one year it has changed 30.81% and within that year its 52-week high was 17.10 and its 52-week low was 11.35. BOJA stock is 41.76% above its 52 Week Low.

Our calculations result in a 200 day moving average of 15.10 and a 50 day moving average of 16.07. Right now, BOJA stock is trading 6.59% above its 200 day moving average.

SeekingAlpha:  Buyout of Bojangles’ closes


The company has a market cap of $611.0m with 38.0m shares outstanding and a float of 37.2m shares. Trading volume was 276,627 shares and has experienced an average volume of 656,921 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Bojangles’ was 1.87 which ended on 31st of December 2017, which according to the previous close, that is a PE of 8.60. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.21. The trailing twelve month EPS is 0.75, which comes to a trailing twelve month PE of 21.45.

Base on our calculations, the intrinsic value per share is 15.47, which means it might overvalued by -3.99%

The next earnings report will be: 04-23-2019

The long-term trend of the EPS is an important number as it indicates the present value of Bojangles’; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 6.30% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 1.90% of insider ownership and 103.00% of institutional ownership.

I calculated the beta to be 0.88

Business Wire:  Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 20.25%, return on assets is 9.58%, profit margin is 1.06%, price-to-sales is 1.47 and price-to-book is 2.10.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 3  : Financial Safety Result
 5  : Past Performance Result
 3  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here